ITHACA, N.Y. — Rheonix, Inc., a developer of fully automated molecular testing solutions, will provide a corporate update at the Canaccord Genuity Medical Technology and Diagnostics Forum on Nov. 19 at the Westin Grand Central in New York City. Steve Pemberton, vice president of marketing and sales at Rheonix, will discuss the company’s latest patent for the Rheonix CARD® cartridge, which enables assays to be performed on the Rheonix Encompass Optimum™ instrument, and recent funding series.
Pemberton will illustrate how patent 9,132,398, “Integrated Microfluidic Device and Methods,” for the CARD, which stands for Chemistry and Reagent Device, enables adoption of advanced molecular technology by laboratories of all types that are capable of designing and implementing their own assays. The innovative and functional design of the CARD makes molecular testing simpler and easier to perform and delivers a fully automated molecular assay at a fraction of the cost of other options. All assay steps are performed within the fully enclosed cartridge, thus eliminating the potential for contamination, reducing user error, and streamlining workflow.
Rheonix recently completed a round of fundraising that raised $28.6 million to further expand the commercialization for its Encompass series of platforms. The investment will also enable new product development and fund existing business needs.
“The ’398 patent and successful series of fundraising confirm the novelty of the Rheonix approach to molecular testing,” said Pemberton. “The Rheonix technology will help make molecular testing more accessible in laboratories worldwide. Our tools are easy to use, cost effective and capable of high throughput and high complexity, addressing obstacles the sample-to-answer molecular testing market faces, such as inefficient workflow and a lack of highly trained staff.”
Pemberton has more than 15 years of experience in sales and product marketing leadership positions within the in-vitro diagnostics market and is a certified medical technologist.
The Encompass Optimum platform is an automated system that streamlines workflow for building and implementing molecular assays. Unmatched versatility allows users the flexibility to configure their own testing and control all aspects of assay performance, while keeping the testing simple and affordable. The Encompass Optimum platform allows users to create their own sample-to-answer, fully automated, complex molecular assays in an easy-to-use format using the Rheonix CARD cartridge. The cartridge automatically manipulates a network of microfluidic pumps to move fluids through the channels of the CARD and run several biological samples through a fully integrated molecular analysis with no user intervention. The Encompass Optimum platform can dramatically decrease the complexities of creating user-defined testing, while increasing efficiency and accuracy. The Encompass Optimum has been developed for Research Use Only testing and is currently for sale to high complexity laboratories in the diagnostic, food and beverage industries that are capable of developing sample-to-result, highly multiplexed tests.
For more information, visit www.rheonix.com.
About Rheonix:
Rheonix Inc. is committed to improving standards of care by making molecular diagnostics available to more people, in more places, more often. Rheonix, through experienced leadership and creative vision, has developed the Encompass Optimum™ platform, a highly customizable technology with unmatched versatility and affordability for use in research laboratories. The platform performs fully automated, complex molecular assays in an easy-to-use and economical format on the Rheonix CARD® cartridge. With both the Rheonix CARD and Encompass Optimum family of products, Rheonix is well-positioned to penetrate key molecular diagnostic market sectors, from reference labs through point-of-care and everywhere in between. For more information, visit www.rheonix.com.
Help employers find you! Check out all the jobs and post your resume.
